CRSP updates | SGMO Message Board Posts

Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  141811 of 144155  at  2/18/2020 1:08:34 PM  by

MartyC

The following message was updated on 2/18/2020 1:11:09 PM.

 In response to msg 141809 by  spaddy
view thread

Re: CRSP updates

Vertex acquired Exonics a private entity focused on CRISPR Cas9 editing.  They received funding from Cureduchennes which appears to have led to the Vertex decision to buy the IP and program from CRSP to pursue internally with Exonics editing.
 
Appears the 3 addl targets that were triggered by Vertex were CF, DMD, DM1 leaving only CF now that Vertex is taking the other two internal.  Not sure why the small difference in milestone potential though.  $410 per program vs $825 for these two.  So 6 targets became 3 though CRSP gets paid handsomely for DMD and DM1 if successful and has an option to participate by paying for 1/2 dev and co-commercialize.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 370
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
141905 Re: CRSP updates MartyC 2 2/21/2020 4:00:14 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...